Comparison
3 Methylglutaconic Aciduria Type 5 C1857776 vs 17p11 2 Microduplication Syndrome C2931246
Clinical comparison between 3 Methylglutaconic Aciduria Type 5 and 17p11 2 Microduplication Syndrome for differential diagnosis and treatment planning.
3 Methylglutaconic Aciduria Type 5 C1857776
A genetic mitochondrial disorder that often causes movement problems, muscle stiffness, and developmental delay. Some forms involve the optic nerve and auditory system. Management focuses on supportive care and addressing specific symptoms.
17p11 2 Microduplication Syndrome C2931246
A chromosomal condition involving duplication on chromosome 17, related to Potocki-Lupski syndrome. Features often include developmental delays, learning challenges, and distinctive facial features.
6 comparison axes
Onset
3 Methylglutaconic Aciduria Type 5 C1857776
0-5
17p11 2 Microduplication Syndrome C2931246
0-null
Onset patterns differ
Severity
3 Methylglutaconic Aciduria Type 5 C1857776
severe
17p11 2 Microduplication Syndrome C2931246
moderate
Different severity levels
Chronic
3 Methylglutaconic Aciduria Type 5 C1857776
Chronic
17p11 2 Microduplication Syndrome C2931246
Chronic
Differing course
Communicable
3 Methylglutaconic Aciduria Type 5 C1857776
No
17p11 2 Microduplication Syndrome C2931246
No
Different transmission
Body System
3 Methylglutaconic Aciduria Type 5 C1857776
metabolic
17p11 2 Microduplication Syndrome C2931246
congenital
Same/different system
Category
3 Methylglutaconic Aciduria Type 5 C1857776
metabolic
17p11 2 Microduplication Syndrome C2931246
genetic
Different category
Bottom line
3-methylglutaconic-aciduria-type-5-C1857776 and 17p11-2-microduplication-syndrome-C2931246 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Methylglutaconic Aciduria Type 5 C1857776 | 17p11 2 Microduplication Syndrome C2931246 | Discriminating power |
|---|---|---|---|
| Movement and muscle tone | Movement problems and muscle stiffness are often described. | Not a defining feature in the supplied description. | Moderate |
| Development | Developmental delay may occur with metabolic features. | Developmental delay and learning challenges are common features. | Low |
| Sensory and facial findings | Some forms involve optic nerve and hearing pathways. | Distinctive facial features may be present. | Moderate |
When to favor each condition
Choose 3 Methylglutaconic Aciduria Type 5 C1857776 when
Early childhood neurologic and metabolic presentation
Supplied onset is 0–5 years with a metabolic classification.
Moderate
Movement disorder with stiffness
These features are specifically described for the left condition.
Moderate
Suspected mitochondrial disease
The source identifies a genetic mitochondrial disorder.
High
Choose 17p11 2 Microduplication Syndrome C2931246 when
Congenital developmental presentation
The source classifies it as congenital and chromosomal.
Moderate
Learning difficulties with facial features
These are the principal described clinical features.
Moderate
Suspected Potocki-Lupski-related duplication
The source links it to 17p11.2 duplication.
High
How key tests differ
| Test | 3 Methylglutaconic Aciduria Type 5 C1857776 | 17p11 2 Microduplication Syndrome C2931246 | Interpretation |
|---|---|---|---|
| Metabolic evaluation | May support a metabolic or mitochondrial process; exact results are not established here. | No characteristic metabolic abnormality is supplied. | An abnormal result is not itself a diagnosis. |
| Chromosomal microarray | Not the defining test in the supplied data. | May identify a 17p11.2 microduplication. | Genetic confirmation requires specialist interpretation. |
| Ophthalmologic and audiologic assessment | May be relevant because some forms affect optic and auditory systems. | No specific sensory abnormality is established by the source. | Findings guide supportive care rather than proving either diagnosis. |
Prognosis comparison
3 Methylglutaconic Aciduria Type 5 C1857776
- Outcome
- Often a severe chronic condition, but individual outcome is not established.
- Factors
- Movement impairment, developmental delay, and possible sensory involvement.
17p11 2 Microduplication Syndrome C2931246
- Outcome
- Often moderate and chronic, with substantial individual variation.
- Factors
- Developmental delay, learning needs, and associated congenital features.
Time frame: Childhood onset is described; long-term outcomes are not quantified.
Supportive care, associated findings, and specialist follow-up influence function.
Complications comparison
| Complication | Presentation |
|---|---|
| Neurologic impairment | Movement problems, stiffness, and developmental delay may be substantial. Developmental and learning challenges are described. Severity and course vary; exact complication rates are not supplied. |
| Sensory involvement | Optic-nerve or auditory involvement may occur in some forms. Not established from the supplied description. Absence from the source does not exclude individual findings. |
| Functional disability | Classified as severe and chronic. Classified as moderate and chronic. These labels do not predict an individual outcome. |
Patient education highlights
- HighDiagnosis
Neither label should be assigned from symptoms alone; genetic or metabolic confirmation and clinician review are needed.
- HighCare
Management is supportive and symptom-directed. No treatment dose or cure is established here.
- MediumInheritance counseling
A genetics professional can explain family implications; transmission details are not provided in the source.